Bryn Pharma is a privately held pharmaceutical company dedicated to finding novel therapeutic solutions, with operations based in locations such as Raleigh, North Carolina and Lebanon, New Jersey.
Subscribe to see Bryn Pharma, LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Bryn Pharma, LLC is a biotechnology company headquartered in United States. Its most recent funding round raised $4.7M in April 2025. Xcout tracks 13 named people at Bryn Pharma, LLC, including Steven Killmeyer (CFO).
7 more named people on record for Bryn Pharma, LLC, with roles, board committees and tenure — see the full roster →
The 4 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $4.7M | — | |
| SEC Form D filing | $26.7M | — | |
| SEC Form D filing | $43.5M | — | |
| — | $11M | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Bryn Pharma, LLC's closest competitors — see the full list of competitors and alternatives →
Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company committed to developing advanced therapeutics that address unmet medical needs. The company is headquartered in Raleigh and Research Triangle Park, North Carolina.
BreStem Therapeutics, Inc. is a clinical-stage biotechnology company located in Raleigh, North Carolina, focused on developing novel therapeutics to fight various diseases.
Aton Pharma, Inc. is a pharmaceutical manufacturing company founded in 2001. The company has locations including Lawrenceville, New Jersey and New York City. It is engaged in pharmaceutical development and drug pipelines.
Lisata Therapeutics is a clinical-stage pharmaceutical company headquartered in Basking Ridge, New Jersey, dedicated to developing advanced therapies to improve the treatment of various serious diseases.
Ayala Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Monmouth Junction, New Jersey. The company focuses on developing targeted therapeutics for rare tumors and aggressive cancers. It engages in clinical research and asset management within the biotechnology and pharmaceutical sector.
VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis. Additionally, the company is progressing VYN201, a bromodomain and extra-terminal (BET) inhibitor designed to target a range of immuno-inflammatory disorders, notably those affecting the skin. A further asset is VYN202, which comprises BET inhibitor compounds engineered for selective action on bromodomain 2. Established in 2003, the firm was formerly recognized as Menlo Therapeutics Inc. before officially changing its corporate identity to VYNE Therapeutics Inc. in September 2020. The company's principal operations are based in Bridgewater, New Jersey.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Bryn Pharma, LLC? Suggest a correction · Work at Bryn Pharma, LLC? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.